What Do "None," "Mild," "Moderate," "Severe," and "Very Severe" Mean to Patients With Cancer? Content Validity of PRO-CTCAE™ Response Scales.
作者信息
Atkinson Thomas M, Hay Jennifer L, Dueck Amylou C, Mitchell Sandra A, Mendoza Tito R, Rogak Lauren J, Minasian Lori M, Basch Ethan
机构信息
Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Memorial Sloan Kettering Cancer Center, New York, New York, USA.
出版信息
J Pain Symptom Manage. 2018 Mar;55(3):e3-e6. doi: 10.1016/j.jpainsymman.2017.10.024. Epub 2017 Nov 10.
Abstract
摘要
相似文献
1
What Do "None," "Mild," "Moderate," "Severe," and "Very Severe" Mean to Patients With Cancer? Content Validity of PRO-CTCAE™ Response Scales.“无”“轻度”“中度”“重度”和“极重度”对癌症患者意味着什么？PRO-CTCAE™反应量表的内容效度。
J Pain Symptom Manage. 2018 Mar;55(3):e3-e6. doi: 10.1016/j.jpainsymman.2017.10.024. Epub 2017 Nov 10.
2
Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer.基于认知访谈的癌症青少年患者报告不良事件通用术语标准结局版本的验证
J Pain Symptom Manage. 2017 Apr;53(4):759-766. doi: 10.1016/j.jpainsymman.2016.11.006. Epub 2017 Jan 3.
3
Comparison of EORTC QLQ-C30 and PRO-CTCAE™ Questionnaires on Six Symptom Items.EORTC QLQ-C30 和 PRO-CTCAE™ 问卷在六个症状项目上的比较。
J Pain Symptom Manage. 2018 Sep;56(3):421-429. doi: 10.1016/j.jpainsymman.2018.05.017. Epub 2018 May 25.
4
Linguistic validation of the simplified Chinese version of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).美国国家癌症研究所患者报告结局版通用不良事件术语标准（PRO-CTCAE™）简体中文版的语言验证。
BMC Cancer. 2020 Nov 26;20(1):1153. doi: 10.1186/s12885-020-07631-5.
5
Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study.癌症患者免疫检查点抑制剂治疗中监测症状性毒性的患者报告结局：德尔菲研究。
Eur J Cancer. 2021 Nov;157:225-237. doi: 10.1016/j.ejca.2021.08.026. Epub 2021 Sep 15.
6
Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).对美国国家癌症研究所患者报告结局版通用不良事件术语标准（PRO-CTCAE）进行认知访谈。
Qual Life Res. 2014 Feb;23(1):257-69. doi: 10.1007/s11136-013-0470-1. Epub 2013 Jul 20.
7
Validity and comprehensibility of outcome measures in children with shoulder and elbow disorders: creation of a new Pediatric and Adolescent Shoulder and Elbow Survey (Pedi-ASES).儿童肩肘疾病结局评估工具的有效性和可理解性：新的儿童青少年肩肘评估问卷（Pedi-ASES）的制定。
J Shoulder Elbow Surg. 2018 Jul;27(7):1162-1171. doi: 10.1016/j.jse.2017.11.009. Epub 2018 Jan 5.
8
Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).德国患者报告的不良事件通用术语标准（PRO-CTCAE™）版本的验证。
Ann Oncol. 2016 Dec;27(12):2294-2299. doi: 10.1093/annonc/mdw422. Epub 2016 Sep 28.
9
Validity and Reliability of the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events.儿科患者报告结局通用术语标准不良事件版本的有效性和可靠性。
J Natl Cancer Inst. 2020 Nov 1;112(11):1143-1152. doi: 10.1093/jnci/djaa016.
10
Dutch translation and linguistic validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™).美国国立癌症研究所不良事件通用术语标准患者报告结局版（PRO-CTCAE™）的荷兰语翻译及语言验证。
J Patient Rep Outcomes. 2020 Oct 6;4(1):81. doi: 10.1186/s41687-020-00249-y.
引用本文的文献
1
Towards Personalized Radiotherapy in Pelvic Cancer: Patient-Related Risk Factors for Late Radiation Toxicity.迈向盆腔癌的个性化放疗：晚期放射毒性的患者相关风险因素
Curr Oncol. 2025 Jan 17;32(1):47. doi: 10.3390/curroncol32010047.
2
Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®).确定患者报告的不良事件通用术语标准（PRO-CTCAE®）中恶化情况的有意义的个体水平变化阈值。
Qual Life Res. 2025 Feb;34(2):495-507. doi: 10.1007/s11136-024-03819-5. Epub 2024 Nov 6.
3
Statistical properties of items and summary scores from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a diverse cancer sample.不同癌症样本中患者报告的不良事件通用术语标准（PRO-CTCAE）的项目和汇总分数的统计特性。
Clin Trials. 2025 Apr;22(2):161-169. doi: 10.1177/17407745241286065. Epub 2024 Oct 23.
4
Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag.采用国家癌症研究所患者报告结局版通用不良事件术语标准评估肺动脉高压治疗耐受性：口服塞乐西帕的现用和曾用患者定性研究结果。
J Patient Rep Outcomes. 2023 Dec 18;7(1):134. doi: 10.1186/s41687-023-00673-w.
5
Feasibility of a Text Messaging-Integrated and Chatbot-Interfaced Self-Management Program for Symptom Control in Patients With Gastrointestinal Cancer Undergoing Chemotherapy: Pilot Mixed Methods Study.一项针对接受化疗的胃肠道癌症患者进行症状控制的短信集成和聊天机器人接口自我管理项目的可行性：混合方法试点研究
JMIR Form Res. 2023 Nov 10;7:e46128. doi: 10.2196/46128.
6
A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events.定制的 I 期特定患者报告结局（PRO）调查，以捕捉症状性不良事件的患者体验。
Br J Cancer. 2023 Sep;129(4):612-619. doi: 10.1038/s41416-023-02307-w. Epub 2023 Jul 7.
7
Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period.PRO-CTCAE® 采用 24 小时回顾期的日常报告的可靠性和有效性。
Qual Life Res. 2023 Jul;32(7):2047-2058. doi: 10.1007/s11136-023-03374-5. Epub 2023 Mar 10.
8
Effects of a Geriatric Assessment Intervention on Patient-Reported Symptomatic Toxicity in Older Adults With Advanced Cancer.老年综合评估干预对晚期癌症老年患者报告的症状性毒性的影响。
J Clin Oncol. 2023 Feb 1;41(4):835-846. doi: 10.1200/JCO.22.00738. Epub 2022 Nov 10.
9
Identifying meaningful change on PROMIS short forms in cancer patients: a comparison of item response theory and classic test theory frameworks.在癌症患者中识别 PROMIS 简式的有意义变化：项目反应理论和经典测试理论框架的比较。
Qual Life Res. 2023 May;32(5):1355-1367. doi: 10.1007/s11136-022-03255-3. Epub 2022 Sep 24.
10
Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®).患者报告结局常用术语标准不良事件（PRO-CTCAE®）意大利语版的文化适应性调整。
Tumori. 2023 Jun;109(3):324-334. doi: 10.1177/03008916221099558. Epub 2022 Jun 8.
本文引用的文献
1
Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).癌症临床试验中的患者报告结局：使用美国国立癌症研究所不良事件通用术语标准的患者报告结局版本（PRO-CTCAE）测量症状性不良事件。
Am Soc Clin Oncol Educ Book. 2016;35:67-73. doi: 10.1200/EDBK_159514.
2
Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust.高阶模型的复制与验证表明，欧洲癌症研究与治疗组织生活质量核心问卷（EORTC QLQ-C30）的综合得分是可靠的。
J Clin Epidemiol. 2016 Jan;69:79-88. doi: 10.1016/j.jclinepi.2015.08.007. Epub 2015 Sep 28.
3
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).美国国家癌症研究所患者报告结局版通用不良事件术语标准（PRO-CTCAE）的有效性和可靠性。
JAMA Oncol. 2015 Nov;1(8):1051-9. doi: 10.1001/jamaoncol.2015.2639.
4
Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).国家癌症研究所患者报告结局版通用不良事件术语标准（PRO-CTCAE）的制定。
J Natl Cancer Inst. 2014 Sep 29;106(9). doi: 10.1093/jnci/dju244. Print 2014 Sep.
5
Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).对美国国家癌症研究所患者报告结局版通用不良事件术语标准（PRO-CTCAE）进行认知访谈。
Qual Life Res. 2014 Feb;23(1):257-69. doi: 10.1007/s11136-013-0470-1. Epub 2013 Jul 20.
6
Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding.内容效度——在新开发的用于医疗产品评估的患者报告结局（PRO）工具中建立和报告证据：ISPOR PRO 良好研究实践工作组报告：第 2 部分——评估受访者的理解。
Value Health. 2011 Dec;14(8):978-88. doi: 10.1016/j.jval.2011.06.013. Epub 2011 Oct 10.
7
Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument.内容效度——在新开发的用于医疗产品评估的患者报告结局（PRO）工具中建立和报告证据：ISPOR PRO 良好研究实践工作组报告：第 1 部分——为新 PRO 工具征集概念。
Value Health. 2011 Dec;14(8):967-77. doi: 10.1016/j.jval.2011.06.014. Epub 2011 Oct 13.
8
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.欧洲癌症研究与治疗组织QLQ-C30：一种用于肿瘤学国际临床试验的生活质量评估工具。
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.
Zotero 插件